<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514865</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-2333POU007</org_study_id>
    <nct_id>NCT00514865</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients
      with Recurrent Major Depressive Disorder
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to treatment endpoint in the MADRS total score</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to treatment endpoint in the HAM-D17, QIDS-SR16, CGI-S, CGI-I, PGI score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-2 mg of ONO-2333</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-10 mg of ONO-2333</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2333Ms</intervention_name>
    <description>5-10 mg QD for 8 weeks</description>
    <arm_group_label>E2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2333Ms</intervention_name>
    <description>0 mg QD for 8 weeks</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2333Ms</intervention_name>
    <description>1-2 mg QD for 8 weeks</description>
    <arm_group_label>E1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with recurrent major depressive disorder

        Exclusion Criteria:

          -  Patients with treatment resistance for depression

          -  History of alcohol abuse/dependence, substance abuse/dependence within 6 months

          -  Has clinically significant unstable medical condition

          -  Has significant risk of suicide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsutoshi Hatakeyama, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharma USA Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ono Pharma Investigtional Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <disposition_first_submitted>November 30, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 25, 2013</disposition_first_posted>
  <last_update_submitted>November 30, 2013</last_update_submitted>
  <last_update_submitted_qc>November 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ONO-2333Ms</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

